Role of cytokines and toll-like receptors in the immunopathogenesis of guillain-barré syndrome

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Nyati, Kishan Kumar ^a   Prasad, Kashi Nath ^b  

^a OSAKA UNIVERSITY   (Japan)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; TOLL LIKE RECEPTOR; EPITOPE;

CYTOKINE PRODUCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; IMMUNOTHERAPY; MOLECULAR PATHOLOGY; NONHUMAN; REVIEW; ANIMAL; AUTOIMMUNITY; CAMPYLOBACTER JEJUNI; CAMPYLOBACTERIOSIS; CHEMISTRY; GENE EXPRESSION REGULATION; GUILLAIN-BARRE SYNDROME; IMMUNE SYSTEM; IMMUNOLOGY; INFLAMMATION; METABOLISM;

ANIMALS; AUTOIMMUNITY; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; CYTOKINES; EPITOPES; GENE EXPRESSION REGULATION; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNE SYSTEM; INFLAMMATION; TOLL-LIKE RECEPTORS;

EID: 84912001236     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/758639     Document Type: Review

References (84)

1. Griffin J. W., Li C. Y., Ho T. W., Tian M., Gao C. Y., Xue P., Mishu B., Cornblath D. R., Macko C., McKhann G. M., Asbury A. K., Pathology of the motor-sensory axonal guillain-barré syndrome. Annals of Neurology 1996 39 1 17 28 10.1002/ana.410390105 2-s2.0-0030065669
2. Kuwabara S., Ogawara K., Misawa S., Koga M., Mori M., Hiraga A., Kanesaka T., Hattori T., Yuki N., Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barré syndrome. Neurology 2004 63 3 529 533 10.1212/01.WNL.0000133205.05169.04 2-s2.0-3543097490
3. Vriesendorp F. J., Insights into Campylobacter jejuni -induced Guillain-Barre syndrome from the Lewis rat model of experimental allergic neuritis. Journal of Infectious Diseases 1997 176 6 S164 S168 10.1086/513787 2-s2.0-0030712862
4. Hughes R., Atkinson P., Coates P., Hall S., Leibowitz S., Sural nerve biopsies in Guillain-Barre syndrome: axonal degeneration and macrophage-associated demyelination and absence of cytomegalovirus genome. Muscle and Nerve 1992 15 5 568 575 10.1002/mus.880150506 2-s2.0-0026575615
5. Brechenmacher C., Vital C., Deminiere C., Guillain-Barre syndrome: an ultrastructural study of peripheral nerve in 65 patients. Clinical Neuropathology 1987 6 1 19 24 2-s2.0-0023161334
6. Vallat J. M., Leboutet M. J., Jauberteau M. O., Tabaraud F., Couratier P., Akani F., Widenings of the myelin lamellae in a typical Guillain-Barre syndrome. Muscle and Nerve 1994 17 4 378 380 10.1002/mus.880170403 2-s2.0-0028220254
7. Griffin J. W., Stoll G., Li C. Y., Tyor W., Cornblath D. R., Macrophage responses in inflammatory demyelinating neuropathies. Annals of Neurology 1990 27 supplement 1 S64 S68 10.1002/ana.410270717 2-s2.0-0025283758
8. Sawant-Mane S., Clark M. B., Koski C. L., In vitro demyelination by serum antibody from patients with Guillain-Barré syndrome requires terminal complement complexes. Annals of Neurology 1991 29 4 397 404 10.1002/ana.410290410 2-s2.0-0025869221
9. Sawant-Mane S., Estep A. III, Koski C. L., Antibody of patients with Guillain-Barré syndrome mediates complement-dependent cytolysis of rat Schwann cells: susceptibility to cytolysis reflects Schwann cell phenotype. Journal of Neuroimmunology 1994 49 1-2 145 152 10.1016/0165-5728(94)90190-2 2-s2.0-0028343878
10. Birchem R., Mithen F. A., L'Empereur K. M., Wessels M. M., Ultrastructural effects of Guillain-Barre serum in cultures containing only rat Schwann cells and dorsal root ganglion neurons. Brain Research 1987 421 1-2 173 185 10.1016/0006-8993(87)91288-1 2-s2.0-0023632192
11. Hartung H.-P., Schwenke C., Bitter-Suermann D., Toyka K. V., Guillain-barré syndrome: activated complement components C3a and C5a in CSF. Neurology 1987 37 6 1006 1009 10.1212/WNL.37.6.1006 2-s2.0-0023160287
12. Koski C. L., Sanders M. E., Swoveland P. T., Lawley T. J., Shin M. L., Frank M. M., Joiner K. A., Activation of terminal components of complement in patients with Guillain-Barre syndrome and other demyelinating neuropathies. Journal of Clinical Investigation 1987 80 5 1492 1497 10.1172/JCI113231 2-s2.0-0023577541
13. Magira E. E., Papaioakim M., Nachamkin I., Asbury A. K., Li C. Y., Ho T. W., Griffin J. W., McKhann G. M., Monos D. S., Differential distribution of HLA-DQ β /DR β epitopes in the two forms of Guillain-Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ β epitopes associated with susceptibility to and protection from AIDP. Journal of Immunology 2003 170 6 3074 3080 10.4049/jimmunol.170.6.3074 2-s2.0-0347927276
14. Akira S., Takeda K., Kaisho T., Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunology 2001 2 8 675 680 10.1038/90609 2-s2.0-0034886143
15. Kopp E. B., Medzhitov R., The Toll-receptor family and control of innate immunity. Current Opinion in Immunology 1999 11 1 13 18 10.1016/S0952-7915(99)80003-X 2-s2.0-0033067894
16. Lisak R. P., Skundric D., Bealmear B., Ragheb S., The role of cytokines in Schwann cell damage, protection, and repair. Journal of Infectious Diseases 1997 176 6 S173 S179 10.1086/513788 2-s2.0-0030657639
17. Nyati K. K., Prasad K. N., Rizwan A., Verma A., Paliwal V. K., TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barré syndrome. Archives of Neurology 2011 68 4 445 452 10.1001/archneurol.2011.51 2-s2.0-79953894884
18. Press R., Deretzi G., Zou L. P., Zhu J., Fredman P., Lycke J., Link H., IL-10 and IFN- γ in Guillain-Barre syndrome. Journal of Neuroimmunology 2001 112 1-2 129 138 10.1016/S0165-5728(00)00388-X 2-s2.0-0035213393
19. Nyati K. K., Prasad K. N., Rizwan A., Verma A., Paliwal V. K., Pradhan S., Lymphocyte transformation test detects a response to Campylobacter jejuni antigens in patients with Guillain-Barré syndrome. Medical Microbiology and Immunology 2010 199 2 109 116 10.1007/s00430-010-0144-3 2-s2.0-77953284699
20. Nyati K. K., Prasad K. N., Kharwar N. K., Soni P., Husain N., Agrawal V., Jain A. K., Immunopathology and Th1/Th2 immune response of Campylobacter jejuni -induced paralysis resembling Guillain-Barré syndrome in chicken. Medical Microbiology and Immunology 2012 201 2 177 187 10.1007/s00430-011-0220-3 2-s2.0-84863459466
21. Zhu J., Mix E., Link H., Cytokine production and the pathogenesis of experimental autoimmune neuritis and Gulllain-Barre syndrome. Journal of Neuroimmunology 1998 84 1 40 52 10.1016/S0165-5728(97)00238-5 2-s2.0-0032054104
22. Kikly K., Liu L., Na S., Sedgwick J. D., The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation. Current Opinion in Immunology 2006 18 6 670 675 10.1016/j.coi.2006.09.008 2-s2.0-33750282677
23. Langowski J. L., Zhang X., Wu L., Mattson J. D., Chen T., Smith K., Basham B., McClanahan T., Kastelein R. A., Oft M., IL-23 promotes tumour incidence and growth. Nature 2006 442 7101 461 465 10.1038/nature04808 2-s2.0-33746534417
24. Hu W., Dehmel T., Pirhonen J., Hartung H.-P., Kieseier B. C., Interleukin 23 in acute inflammatory demyelination of the peripheral nerve. Archives of Neurology 2006 63 6 858 864 10.1001/archneur.63.6.858 2-s2.0-33745108866
25. Chabaud M., Aarvak T., Garnero P., Natvig J. B., Miossec P., Potential contribution of IL-17-producing Th1 cells to defective repair activity in joint inflammation: partial correction with Th2-promoting conditions. Cytokine 2001 13 2 113 118 10.1006/cyto.2000.0811 2-s2.0-0035924912
26. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunology 2005 6 11 1123 1132 10.1038/ni1254 2-s2.0-27544490377
27. Mathur A. N., Chang H.-C., Zisoulis D. G., Kapur R., Belladonna M. L., Kansas G. S., Kaplan M. H., T-bet is a critical determinant in the instability of the IL-17-secreting T-helper phenotype. Blood 2006 108 5 1595 1601 10.1182/blood-2006-04-015016 2-s2.0-33748174156
28. Zhang Z., Zhang Z.-Y., Schluesener H. J., Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. Journal of Immunology 2009 183 5 3081 3091 10.4049/jimmunol.0901088 2-s2.0-70349247894
29. Chi L. J., Xu W. H., Zhang Z. W., Huang H. T., Zhang L. M., Zhou J., Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System 2010 15 4 345 356 10.1111/j.1529-8027.2010.00294.x 2-s2.0-78650815791
30. Li S., Yu M., Li H., Zhang H., Jiang Y., IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome. Mediators of Inflammation 2012 2012 7 260473 10.1155/2012/260473 2-s2.0-84867921583
31. Liang S.-L., Wang W.-Z., Huang S., Wang X.-K., Zhang S., Wu Y., Th17 helper cell and T-cell immunoglobulin and mucin domain 3 involvement in GuillainBarré syndrome. Immunopharmacology and Immunotoxicology 2012 34 6 1039 1046 10.3109/08923973.2012.697469 2-s2.0-84868111908
32. Pelidou S.-H., Zou L.-P., Deretzi G., Oniding C., Mix E., Zhu J., Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role. Experimental Neurology 2000 163 1 165 172 10.1006/exnr.2000.7357 2-s2.0-0034106554
33. Shen F., Gaffen S. L., Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine 2008 41 2 92 104 10.1016/j.cyto.2007.11.013 2-s2.0-38949194566
34. Zepp J., Wu L., Li X., IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends in Immunology 2011 32 5 232 239 10.1016/j.it.2011.02.007 2-s2.0-79955636935
35. Li C., Zhao P., Sun X., Che Y., Jiang Y., Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with guillain-barré syndrome. Mediators of Inflammation 2013 2013 9 639712 10.1155/2013/639712 2-s2.0-84885571613
36. McNamee E. N., Masterson J. C., Jedlicka P., McManus M., Grenz A., Collins C. B., Nold M. F., Nold-Petry C., Bufler P., Dinarello C. A., Rivera-Nieves J., Interleukin 37 expression protects mice from colitis. Proceedings of the National Academy of Sciences of the United States of America 2011 108 40 16711 16716 10.1073/pnas.1111982108 2-s2.0-80053624991
37. Sakai N., van Sweringen H. L., Belizaire R. M., Quillin R. C., Schuster R., Blanchard J., Burns J. M., Tevar A. D., Edwards M. J., Lentsch A. B., Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. Journal of Gastroenterology and Hepatology 2012 27 10 1609 1616 10.1111/j.1440-1746.2012.07187.x 2-s2.0-84866527284
38. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A., Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nature Medicine 2007 13 10 1173 1175 10.1038/nm1651 2-s2.0-34948909646
39. Akashi-Takamura S., Miyake K., Toll-like receptors (TLRs) and immune disorders. Journal of Infection and Chemotherapy 2006 12 5 233 240 10.1007/s10156-006-0477-4 2-s2.0-33751042265
40. Gries M., Davies L., Liu Y., Bachhuber A., Spiegel J., Dillmann U., Hartmann T., Fassbender K., Walter S., Response of Toll-like receptors in experimental Guillain-Barré syndrome: a kinetic analysis. Neuroscience Letters 2012 518 2 154 160 10.1016/j.neulet.2012.04.077 2-s2.0-84861706535
41. Kuijf M. L., Samsom J. N., van Rijs W., Bax M., Huizinga R., Heikema A. P., Van Doorn P. A., Van Belkum A., Van Kooyk Y., Burgers P. C., Luider T. M., Endtz H. P., Nieuwenhuis E. E. S., Jacobs B. C., TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation. The Journal of Immunology 2010 185 1 748 755 10.4049/jimmunol.0903014 2-s2.0-77956207001
42. Huizinga R., van Rijs W., Bajramovic J. J., Kuijf M. L., Laman J. D., Samsom J. N., Jacobs B. C., Sialylation of Campylobacter jejuni endotoxin promotes dendritic cell-mediated B cell responses through CD14-dependent production of IFN- β and TNF-α The Journal of Immunology 2013 191 11 5636 5645 10.4049/jimmunol.1301536 2-s2.0-84888381600
43. Mercier B. C., Cottalorda A., Coupet C.-A., Marvel J., Bonnefoy-Bérard N., TLR2 engagement on CD8 T cells enables generation of functional memory cells in response to a suboptimal TCR signal. Journal of Immunology 2009 182 4 1860 1867 10.4049/jimmunol.0801167 2-s2.0-61449121028
44. Zhang Z. Y., Schluesener H. J., Toll-like receptor-2, CD14 and heat-shock protein 70 in inflammatory lesions of rat experimental autoimmune neuritis. Neuroscience 2009 159 1 136 142 10.1016/j.neuroscience.2008.12.034 2-s2.0-60349096095
45. Laurà M., Mazzeo A., Aguennouz M., Santoro M., Catania M. A., Migliorato A., Calapai G., Vita G., Immunolocalization and activation of nuclear factor- B in the sciatic nerves of rats with experimental autoimmune neuritis. Journal of Neuroimmunology 2006 174 1-2 32 38 10.1016/j.jneuroim.2006.01.004 2-s2.0-33646084180
46. Wang Y. Z., Liang Q. H., Ramkalawan H., Wang Y. L., Yang Y. F., Zhou W. B., Tian F. F., Li J., Yang H., Expression of toll-like receptors 2, 4 and 9 in patients with guillain-barré syndrome. NeuroImmunoModulation 2011 19 1 60 68 10.1159/000328200 2-s2.0-80855147863
47. Schumann R. R., Tapping R. I., Genomic variants of TLR1-It takes (TLR-)two to tango. European Journal of Immunology 2007 37 8 2059 2062 10.1002/eji.200737604 2-s2.0-34547902122
48. Müller M., Stenner M., Wacker K., Ringelstein E. B., Hickey W. F., Kiefer R., Contribution of resident endoneurial macrophages to the local cellular response in experimental autoimmune neuritis. Journal of Neuropathology and Experimental Neurology 2006 65 5 499 507 10.1097/01.jnen.0000229239.43866.d1 2-s2.0-33746302813
49. Beaino W., Trifilieff E., Thiopalmitoylated peptides from the peripheral nervous system myelin P0 protein: synthesis, characterization, and neuritogenic properties. Bioconjugate Chemistry 2010 21 8 1439 1447 10.1021/bc100039u 2-s2.0-77955800392
50. Deng Y.-N., Zhou W.-B., Expression of TLR4 and TLR9 mRNA in Lewis rats with experimental allergic neuritis. NeuroImmunoModulation 2007 14 6 337 343 10.1159/000127433 2-s2.0-44349100526
51. Marta M., Andersson Å., Isaksson M., Kämpe O., Lobell A., Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. European Journal of Immunology 2008 38 2 565 575 10.1002/eji.200737187 2-s2.0-42249109064
52. Pepper M., Dzierszinski F., Wilson E., Tait E., Fang Q., Yarovinsky F., Laufer T. M., Roos D., Hunter C. A., Plasmacytoid dendritic cells are activated by Toxoplasma gondii to present antigen and produce cytokines. Journal of Immunology 2008 180 9 6229 6236 10.4049/jimmunol.180.9.6229 2-s2.0-44449151187
53. + T cell activation via toll-like receptors 1 and 2. Infection and Immunity 2011 79 2 663 673 10.1128/IAI.00806-10 2-s2.0-79251503252
54. Geleijns K., Jacobs B. C., van Rijs W., Tio-Gillen A. P., Laman J. D., van Doorn P. A., Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients. Journal of Neuroimmunology 2004 150 1-2 132 138 10.1016/j.jneuroim.2004.01.003 2-s2.0-1842636929
55. Koga M., Yuki N., Kashiwase K., Tadokoro K., Juji T., Hirata K., Guillain-Barre and Fisher's syndromes subsequent to Campylobacter jejuni enteritis are associated with HLA-B54 and Cw1 independent of anti-ganglioside antibodies. Journal of Neuroimmunology 1998 88 1-2 62 66 10.1016/S0165-5728(98)00072-1 2-s2.0-0032129212
56. Geleijns K., Schreuder G. M. T., Jacobs B. C., Sintnicolaas K., Van Koningsveld R., Meulstee J., Laman J. D., Van Doorn P. A., HLA class II alleles are not a general susceptibility factor in Guillain-barré syndrome. Neurology 2005 64 1 44 49 10.1212/01.WNL.0000148727.02732.01 2-s2.0-11444266912
57. Ma J. J., Nishimura M., Mine H., Kuroki S., Nukina M., Ohta M., Saji H., Obayashi H., Saida T., Kawakami H., Uchiyama T., HLA and T-cell receptor gene polymorphisms in Guillain-Barre syndrome. Neurology 1998 51 2 379 384 10.1212/WNL.51.2.379 2-s2.0-0031754188
58. Prasad K. N., Nyati K. K., Verma A., Rizwan A., Paliwal V. K., Tumor necrosis factor-α polymorphisms and expression in Guillain-Barré syndrome. Human Immunology 2010 71 9 905 910 10.1016/j.humimm.2010.06.013 2-s2.0-77956012788
59. Myhr K.-M., Vågnes K. S., Marøy T. H., Aarseth J. H., Nyland H. I., Vedeler C. A., Interleukin-10 promoter polymorphisms in patients with Guillain-Barré syndrome. Journal of Neuroimmunology 2003 139 1-2 81 83 10.1016/S0165-5728(03)00133-4 2-s2.0-0038208040
60. Arbour N. C., Lorenz E., Schutte B. C., Zabner J., Kline J. N., Jones M., Frees K., Watt J. L., Schwartz D. A., TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nature Genetics 2000 25 2 187 191 10.1038/76048 2-s2.0-0034084438
61. Maeda S., Akanuma M., Mitsuno Y., Hirata Y., Ogura K., Yoshida H., Shiratori Y., Omata M., Distinct mechanism of Helicobacter pylori -mediated NF- B activation between gastric cancer cells and monocytic cells. Journal of Biological Chemistry 2001 276 48 44856 44864 10.1074/jbc.M105381200 2-s2.0-0035977010
62. Rock F. L., Hardiman G., Timans J. C., Kastelein R. A., Bazan J. F., A family of human receptors structurally related to Drosophila Toll. Proceedings of the National Academy of Sciences of the United States of America 1998 95 2 588 593 10.1073/pnas.95.2.588 2-s2.0-0031905311
63. Leadbetter E. A., Rifkin I. R., Hohlbaum A. M., Beaudette B. C., Shlomchik M. J., Marshak-Rothstein A., Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002 416 6881 603 607 10.1038/416603a 2-s2.0-0037061453
64. Nyati K. K., Prasad K. N., Verma A., Singh A. K., Rizwan A., Sinha S., Paliwal V. K., Pradhan S., Association of TLR4 Asp299Gly and Thr399Ile polymorphisms with Guillain-barré syndrome in Northern Indian population. Journal of Neuroimmunology 2010 218 1-2 116 119 10.1016/j.jneuroim.2009.10.018 2-s2.0-73149094059
65. Caporale C. M., Papola F., Fioroni M. A., Aureli A., Giovannini A., Notturno F., Adorno D., Caporale V., Uncini A., Susceptibility to Guillain-Barré syndrome is associated to polymorphisms of CD1 genes. Journal of Neuroimmunology 2006 177 1-2 112 118 10.1016/j.jneuroim.2006.05.018 2-s2.0-33746273756
66. Geleijns K., Roos A., Houwing-Duistermaat J. J., Van Rijs W., Tio-Gillen A. P., Laman J. D., Van Doorn P. A., Jacobs B. C., Mannose-binding lectin contributes to the severity of Guillain-Barré syndrome. Journal of Immunology 2006 177 6 4211 4217 10.4049/jimmunol.177.6.4211 2-s2.0-33748516580
67. Sinha S., Prasad K. N., Jain D., Nyati K. K., Pradhan S., Agrawal S., Immunoglobulin IgG Fc-receptor polymorphisms and HLA class II molecules in Guillain-Barré syndrome. Acta Neurologica Scandinavica 2010 122 1 21 26 10.1111/j.1600-0404.2009.01229.x 2-s2.0-77953337798
68. van Sorge N. M., van Der Pol W.-L., Jansen M. D., Geleijns K. P. W., Kalmijn S., Hughes R. A. C., Rees J. H., Pritchard J., Vedeler C. A., Myhr K.-M., Shaw C., van Schaik I. N., Wokke J. H. J., van Doorn P. A., Jacobs B. C., van De Winkel J. G. J., van Den Berg L. H., Severity of Guillain-Barré syndrome is associated with Fc γ receptor III polymorphisms. Journal of Neuroimmunology 2005 162 1-2 157 164 10.1016/j.jneuroim.2005.01.016 2-s2.0-20144388163
69. Uncini A., Notturno F., Pace M., Caporale C. M., Polymorphism of CD1 and SH2D2A genes in inflammatory neuropathies. Journal of the Peripheral Nervous System 2011 16 1 48 51 10.1111/j.1529-8027.2011.00307.x 2-s2.0-79959618543
70. Pandey J. P., Vedeler C. A., Immunoglobulin KM genes in Guillain-Barré syndrome. Neurogenetics 2003 4 3 147 149 2-s2.0-0038286417
71. Dekker M. J. H. J., van Den Akker E. L. T., Koper J. W., Manenschijn L., Geleijns K., Ruts L., Van Rijs W., Tio-Gillen A. P., van Doorn P. A., Lamberts S. W. J., Jacobs B. C., Effect of glucocorticoid receptor gene polymorphisms in Guillain-Barré syndrome. Journal of the Peripheral Nervous System 2009 14 2 75 83 10.1111/j.1529-8027.2009.00216.x 2-s2.0-69249145190
72. Sharshar T., Durand M.-C., Lefaucheur J.-P., Lofaso F., Raphaël J.-C., Gherardi R. K., Créange A., MMP-9 correlates with electrophysiologic abnormalities in Guillain-Barré syndrome. Neurology 2002 59 10 1649 1651 10.1212/01.WNL.0000033799.58866.7A 2-s2.0-0037180414
73. Kuwabara S., Guillain-Barré syndrome: epidemiology, pathophysiology and management. Drugs 2004 64 6 597 610 10.2165/00003495-200464060-00003 2-s2.0-1842784961
74. Vucic S., Kiernan M. C., Cornblath D. R., Guillain-Barré syndrome: an update. Journal of Clinical Neuroscience 2009 16 6 733 741 10.1016/j.jocn.2008.08.033 2-s2.0-67349199109
75. Sharief M. K., Ingram D. A., Swash M., Thompson E. J., I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology 1999 52 9 1833 1838 10.1212/WNL.52.9.1833 2-s2.0-0032588204
76. van der Meche F. G., Schmitz P. I., A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. The New England Journal of Medicine 1992 326 17 1123 1129 10.1056/NEJM199204233261705 2-s2.0-0026516454
77. Thornton C. A., Ballow M., Safety of intravenous immunoglobulin. Archives of Neurology 1993 50 2 135 136 10.1001/archneur.1993.00540020013009 2-s2.0-0027475961
78. Thornton C. A., Griggs R. C., Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Annals of Neurology 1994 35 3 260 268 10.1002/ana.410350304 2-s2.0-0028271671
79. Raphaël J.-C., Chevret S., Chastang C., Jars-Guincestre M.-C., Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Annals of Neurology 1997 41 3 298 306 10.1002/ana.410410304 2-s2.0-0031047929
80. Vriesendorp F. J., Dmytrenko G. S., Dietrich T., Koski C. L., Anti-peripheral nerve myelin antibodies and terminal activation products of complement in serum of patients with acute brachial plexus neuropathy. Archives of Neurology 1993 50 12 1301 1303 10.1001/archneur.1993.00540120016006 2-s2.0-0027139851
81. Hughes R. A., Swan A. V., Raphaël J.-C., Annane D., van Koningsveld R., van Doorn P. A., Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007 130 9 2245 2257 10.1093/brain/awm004 2-s2.0-34548228508
82. Hughes R. A., Swan A. V., van Doorn P. A., Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database System Review 2012 7 CD002063 2-s2.0-84866446951
83. Hughes R. A., Newsom-Davis J. M., Perkin G. D., Pierce J. M., Controlled trial of prednisolone in acute polyneuropathy. The Lancet 1978 2 8093 750 753 2-s2.0-0018119702
84. Singh N. K., Gupta A., Do corticosteriods influence the disease course or mortality in Guillain-Barre' syndrome? The Journal of Association of Physicians of India 1996 44 1 22 24 2-s2.0-0029685592